Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT. The study focuses on: Development and optimization of staining methods for markers, a critical target in HT-KIT therapeutic mechanism; processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers; comprehensive reporting and insights to support the continued development of HT-KIT.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics regains compliance with Nasdaq listing rules
- Hoth Therapeutics expands IP portfolio with patent application acquisitions
- Biotech Alert: Searches spiking for these stocks today
- 3 Penny Stocks to Watch Now, 1/9/25
- Hoth Therapeutics responds to market rumors, says no plans for offering